Issues & Advocacy

SNMMI's mission with regard to health policy and regulatory affairs is to enhance its credibility, advance its issues, and through leadership become a valued partner among public policy stakeholders.


  • June 27, 2022Aetna Reverses Cardiac PET/CT Non-Coverage & Updates Policy for PSMA Therapy
    SNMMI and ASNC requested that Aetna reverse its non-coverage cardiac PET/CT policy. We are thrilled to communicate that within a few days of receiving our letter, Aetna reversed the policy. Also, Aetna recently updated and published their coverage policy for PSMA imaging for PLUVICTO therapy eligibility.
  • June 24, 2022CMS Reopens NCD for Beta Amyloid PET in Dementia and Neurodegenerative Disease
    On June 16, 2022, the Centers for Medicare and Medicaid Services (CMS) began a reconsideration process for its National Coverage Determination (NCD) for Beta Amyloid Positron Emission Tomography (PET) in Dementia and Neurodegenerative Disease
  • May 16, 2022SNMMI & Partners Urge Congress to Support Increased Federal Research Funding
    SNMMI and 368 members of the Ad Hoc Group for Medical Research sent a letter to Congress requesting that the Labor-HHS Subcommittee be allocated sufficient funding to allow for investment in NIH and other agencies that promote the health of our nation. The letter also urged Congress to work expeditiously to complete FY 2023 appropriations in a timely manner.
  • April 28, 2022SNMMI and Partners Request a Hearing for the FIND Act
    This week, SNMMI and over 70 organizations sent a letter to House Energy and Commerce and Ways and Means Committee Leadership requesting a hearing on the Facilitating Innovative Nuclear Diagnostics (FIND) Act.
  • March 28, 2022SNMMI Hosts AI and Patient Access Summits
    On March 21-23, SNMMI hosted two summits in Bethesda, MD, on Artificial Intelligence and Barriers to Patient Access. The aim of the summits—the first of their kind for the society—was to bring together thought leaders to discuss current obstacles in the field of nuclear medicine and provide solutions. Read the highlights.
  • March 11, 2022New Issue of Clinical Trials Newsletter "Pathways" Now Available
    The February 2022 issue of the SNMMI Clinical Trials Network newsletter, Pathways, is now available online.
  • March 4, 2022SNMMI Supports ARPA-H Act
    SNMMI signed on as a supporting organization to the Advanced Research Project Agency Health (ARPA-H) Act and offered to be a resource as the bill's sponsor continues to refine the legislative text.
  • February 18, 2022SNMMI Congratulates FDA Commissioner Califf
    SNMMI congratulates Robert Califf, MD, on his confirmation as the 25th Commissioner of the U.S. Food and Drug Administration.

  • Click For More Government Relations News